key: cord-0303221-ijgt4jv9
authors: Wang, Mengya; Duong, Thomas L.; Rea, Brandon J.; Waite, Jayme S.; Huebner, Michael W.; Flinn, Harold C.; Russo, Andrew F.; Sowers, Levi P.
title: CGRP Administration into the Cerebellum Evokes Migraine-like Behaviors Predominately in Female Mice
date: 2022-01-25
journal: bioRxiv
DOI: 10.1101/2022.01.24.477577
sha: f5592ead4c1787941adb2ae43c70cb75e6668f32
doc_id: 303221
cord_uid: ijgt4jv9

The neuropeptide calcitonin gene-related peptide (CGRP) is a major player in migraine pathophysiology. Previous preclinical studies demonstrated that intracerebroventricular administration of CGRP caused migraine-like behaviors in mice, but the sites of action in the brain remain unidentified. The cerebellum has the most CGRP binding sites in the central nervous system and is increasingly recognized as both a sensory and motor integration center. The objective of this study was to test whether the cerebellum, particularly the medial cerebellar nuclei (MN), might be a site of CGRP action. In this study, CGRP was directly injected into the right MN of C57BL/6J mice via a cannula. A battery of behavioral tests was done to assess migraine-like behaviors. CGRP caused light aversion measured as decreased time in the light zone even with dim light. The mice also spent more time resting in the dark zone, but not the light, along with decreased rearing and transitions between zones. These behaviors were similar for both sexes. In contrast, significant responses to CGRP were seen only with female mice in the open field assay, von Frey test, and automated squint assay, indicating anxiety, tactile hypersensitivity, and spontaneous pain, respectively. In male mice, the responses had the same trend as females but did not reach statistical significance. No detectable effect of CGRP on gait was observed in either sex. These results suggest that CGRP in the MN causes light aversion in males, while in females, light aversion is accompanied by increased anxiety, tactile hypersensitivity, and spontaneous pain. A caveat is that we cannot exclude contributions from other cerebellar regions in addition to the MN due to diffusion of the injected peptide. These results reveal the cerebellum as a new site of CGRP actions that may contribute to migraine pathophysiology and possibly its prevalence in females.

Introduction 33

Migraine is a neurological disease that affects about 15% of the population (1) and is the second 34 leading cause of disability globally (2). It is characterized by moderate or severe headaches that are accompanied by sensory abnormalities, such as photophobia and allodynia (3). Prevalence in women 36

is about twice as high as in men (1). Despite its high prevalence and large burden to society, the 37 mechanism underlying migraine have yet to be fully elucidated. Over the last few decades, calcitonin 38 gene-related peptide (CGRP) has moved to the forefront in migraine pathophysiology. CGRP levels 39

are elevated in both the ictal and interictal phases in human studies (4-6) and infusion of CGRP 40

induced migraine-like headaches in ~66% of migraine patients (7-10). Most recently, CGRP-based 41 drugs have been shown to effectively alleviate migraine symptoms in about 50% of patients (11, 12) . 42 However, despite the significant advancement of CGRP-based drugs as migraine therapeutics, there 43

is uncertainty regarding the mechanisms by which CGRP induces migraine, especially as to where 44 CGRP is acting. 45

The human studies measuring CGRP levels (4-6) and induction of migraine-like headaches by 46 intravenous CGRP injections (7-10) suggest a peripheral site of action for CGRP in migraine. In 47 addition, the antibodies targeted against CGRP or CGRP receptors have limited ability to cross the 48 blood-brain barrier (13 injection (15) . Those data suggest that increased sensitivity to CGRP in the nervous system can cause 55 migraine-like light-aversive behavior in mice. Finally, it was found that CGRP injection into the 56 posterior thalamic nuclei, an integration center for light and pain signals, was sufficient to induce 57 light aversion in wild-type C57BL/6J mice, even in dim light (18). Together, these data suggest that 58 CGRP can work in the central nervous system to induce migraine-like photophobic behavior in mice. 59

Similar to the thalamus, the cerebellum integrates multiple sensory signals and motor events (19, 20) . 60 While the cerebellum was originally recognized for its role in motor control (21), there is mounting 61 evidence that it also plays important roles in perceptual (22), emotional (23), and cognitive functions 62

(24-26). In particular, it is now appreciated that the cerebellum participates in sensory, emotional, 63 cognitive aspects of pain, and motor control in response to pain (27) . Three lines of evidence support 64 the link between the cerebellum and migraine pathogenesis. First, changes in cerebellar activation 65

(28-30), structure (31-35) (36-38) (39-43), and functional connectivity (44-49) are present in 66 episodic, chronic, and familial hemiplegic migraine patients. When responding to trigeminal stimuli, 67 cerebellar activity and functional connectivity with the thalamus and cortical areas were changed 68 (34), suggesting the cerebellum is involved in processing sensory information from the trigeminal 69 system. Strikingly, migraine patients exhibited decreased cerebellar activation in response to 70 trigeminal nociceptive stimuli after treatment with erenumab, a CGRP receptor antibody (50). 71

Second, migraine patients display cerebellar symptoms, e.g., dizziness, vertigo (51), body sway (52, 72 53), as well as increased body sway accompanied by increased light intensity (54). Third, the 73 cerebellum communicates directly to migraine-related regions, such as the spinal trigeminal nucleus 74

(55-57) and the thalamus (58) via direct neural circuits. These data hint to the importance of the 75 cerebellum in migraine pathophysiology. 76

Curiously, the cerebellum has the highest binding density to CGRP receptor PET ligands in human 77 and rhesus brains (59, 60). The canonical CGRP receptor subunits, receptor activity-modifying 78 protein 1 (RAMP1) and calcitonin receptor-like receptor (CLR), are localized in the human, rhesus 79 and rat cerebellar cortex (61-66) and in the medial cerebellar nuclei (MN, also known as fastigial 80 nuclei in humans) of rats (65). CGRP is also distributed in the cerebellar cortex (61, 62, 65-67) and 81 the MN (65). In addition, as one of the three deep cerebellar nuclei, the MN receives sensory 82 information via vestibular nuclei (68) and projects to migraine-related brain regions including the 83 thalamus (69 Corporation; Supplementary Fig. 1 ). An 8-mm guide cannula was made from a 23-gauge needle (BD 106

PrecisionGlide™) with the ventral portion covered by a ~7-mm, 19-gauge tubing (Supplementary 107 Fig. 1A ). The ~7-mm, 19-gauge tubing is ~2 mm higher than the 23-gauge needle to shield the 108 junction between the guide's top and the dummy or injection cannula after their insertion 109 ( Supplementary Fig. 1A ). The dummy cannula, used to seal and keep the guide cannula free of clogs, 110 was made by crimping a short segment of ~5-mm, 23-gauge tubing to a ~14 mm piece of 30-gauge 111 tubing ( Supplementary Fig. 1B ). The bottom of the 30-gauge tubing was cut to ensure that the 30-112 gauge segment below the ~5-mm, 23-gauge segment is 9 mm. The injection cannula was made by 113 adhering a short segment of ~5-mm, 23-gauge tubing ~5 mm below the top of a ~20-mm piece of 30-114 gauge tubing with adhesive (Pacer Technology) and dental cement (Stoelting) ( Supplementary Fig.  115 1C). The bottom of the 30-gauge tubing was cut to ensure that the 30-gauge segment below the ~5-116 mm, 23-gauge segment is 10 mm. In this manner, the dummy cannula extended 1 mm beyond the 117 end of the guide cannula tip when it was inserted into the guide cannula, while the injection cannula 118 protruded 2 mm from the base of the guide cannula ( Supplementary Fig. 1D ). 119

Stereotaxic implantation of a guide cannula into the MN of the right cerebellum was performed under 120 isoflurane anesthesia (induction 5%, maintenance 1.5%-2%). The coordinates for the right MN are: 121

anterior/posterior (AP), -6.5 mm posterior to bregma; medial/lateral (ML), -0.85 mm lateral to the midline; and dorsal/ventral (DV), -2.7 mm ventral to the pial surface according to the Allen Brain 123

Reference Atlas. Guide cannulas were implanted 2 mm above the MN (AP: -6.5 mm; ML; -0.8 mm; 124 DV: -0.7 mm). The implants were secured with bone anchor screws (Stoelting), adhesive, and dental 125 cement. Dummy cannulas were inserted into guide cannulas when no injection was conducted. After 126 surgery, mice were housed individually to reduce the loss of the guide or dummy cannulas. Mice 127 were given ~10 days to recover from the surgery before testing unless otherwise indicated. 128

Rat The investigator who applied filaments was blinded to the treatments and used the up-and-down 177 method as previously described (78-80). Briefly, filaments were applied for 5 seconds to the skin of 178 the mouse plantar surface, with D (0.07 g) as the starting filament. A withdrawal response was 179 considered when mice withdrew, shook, or licked the tested hind paws. The withdrawal threshold at 180 which 50% of mice withdrew their hind paws was determined based on an established equation (79,  181 80). However, the threshold data produced in this method are not continuous and cannot be analyzed 182 using parametric statistics. Thus, in order to obtain normal distribution, the 50% thresholds (g) were 183

transformed into log format for data analysis and figure plotting. 184

This assay is to evaluate spontaneous pain by measuring the right-eye pixel areas recorded by a 186 camera. Mice were acclimated to a customized collar restraint to reduce stress induced by restraint as 187 well as struggle or head movement as described previously (81 Mice were habituated to the room for one hour prior to any running. Mice first were placed in the 204 chamber of the DigiGait apparatus for 1 min to allow them to explore the chamber. The belt was then 205 turned on and mice were run at 16 cm/s, an optimal speed predetermined in C57BL/6J mice. Images 206 of the paws were ventrally captured during the run. Each mouse ran until roughly 3-5 seconds of 207 continuous gait was observed, a range sufficient to acquire adequate quantification of gait 208

parameters. Mice underwent recordings before PBS or CGRP injection as the baseline. After 209 injection, mice recovered in the home cages for one hour prior to another recording. A minimum of a 210 one-hour interval was allotted between baseline and treatment trials to allow mice to recover from the 211 previous running. 212

The mouse paw prints were analyzed by DigiGait Analysis to identify stride length and frequency. A 213 complete stride was defined as the portion of foot strike to subsequent foot strike on the treadmill belt 214 of the same foot. 215

After finishing all the behavioral tests, the injection sites were identified by the injection cannula tip, 217

or To reduce the number of animals used in this study, the cannula system was used to allow the same 234 mouse to undergo different assays. The first cohort was tested in the light/dark assay, open field 235 assay, von Frey test, and automated squint assay. Because of the COVID-19 pandemic, the second 236 cohort which had been exposed to the light/dark assay, open field assay and von Frey test were 237 euthanized to minimize the burden in the animal facility. To repeat experiments in the automated 238 squint assay, a third cohort was included. Unlike the previous two cohorts, the third cohort was first 239 housed in groups after surgery. However, due to the high rate of dummy cannula loss in group 240

housing conditions for about one week, mice were then housed individually instead, consistent with 241 earlier cohorts. Von Frey test, gait dynamic and automated squint assays were performed in this 242

cohort. Data from all cohorts were pooled for the final analysis. 243

The order of light/dark assay and open field assay was switched in the two cohorts to avoid an order 244

bias. All the mice received the same treatment in the light/dark and open field assays to ensure the 245 consistency. The same treatment in the light/dark assay was also given in the squint and gait dynamic 246 assays. One cohort received crossover treatment in the automated squint assay. To ensure the 247 withdrawal threshold in the von Frey test was comparable in control and experimental groups, mice 248

were divided into two groups using a randomization protocol based on the baseline threshold. Mice 249

were allowed to recover in their home cages for at least one day between each behavioral test. test was performed for bar graphs with scatter points to compare the effect of each treatment. 266 A total of 3 mice died during the surgical procedure and one mouse lost the guide cannula before 267 running any behavioral test. Two mice from the light/dark assay and one mouse from the open field 268 assay were excluded due to chamber recording problems. In the von Frey test, 4 total mice were 269 excluded: 3 mice due to the blockage of injection cannulas and one mouse due to the loss of the 270 guide cannula. In the gait dynamic assay, 2 mice were excluded due to a video recording problem. In 271 the automated squint assay, 2 mice were excluded due to the loss of the guide cannulas, 3 mice due to 272 the blockage of injection cannulas, and 5 mice due to the poor habituation in the restraint or poor eye 273 recognition by the software. Mouse numbers used for each experiment are reported in the figure  274 legends. 275 3

Results 276

We injected CGRP into the MN of the right cerebellum via permanently placed cannulas and exposed 279 the mice to the light/dark assay in dim light (55 lux) one hour post-injection. Light aversion was 280 expressed as both a function of time over the 30-min testing period (Fig. 1A ) and the average time in 281 light for individual mice per 5 min interval (Fig. 1B) . Regardless of sex, mice injected with CGRP 282 spent less time in the light than those injected with PBS during the 30-min testing time (Fig. 1A,  283 left). On average, the PBS-treated mice spent 141 seconds in the light per 5-min interval, and CGRP-284 treated mice spent 55 seconds (Fig.1B, left) . When data were separated by sex, both male and female 285 mice spent significantly less time in light after CGRP injection than those with PBS injection (Fig.  286 1A and B, middle and right). For all mice, confirmation of the targeting site was performed. The 287

injection sites for mice in all behavioral tests are shown in Fig. 1C . Among 21 mice that experienced 288 the light/dark assay, injection sites for 6 mice were not in or near the MN, primarily in the cerebellar 289 cortex. However, these 6 off-target mice did not display significant differences in time in light from 290 the on-target mice (data not shown). However, it should be noted that it is underpowered for off-291 target mice. Together, these data demonstrate that CGRP injection into the MN induces light-292 aversive behavior in both male and female mice. 293

Resting behavior was evaluated in the same light/dark assay. No difference was observed in the 294 percent resting time in the light zone between CGRP-and PBS-injected mice ( Fig. 2A and B, upper  295 panel). In contrast, in the dark zone, CGRP-injected mice spent more time resting than PBS-injected 296 mice across both sexes ( Fig. 2A and B lower panel) . In addition, CGRP-injected mice had 297 significantly fewer rearings (vertical beams breaks) in both the light and dark zones across sexes 298 ( Fig. 2C and D) . While there was a trend, the decreased rearing did not reach statistical significance 299

in the male or female groups after CGRP injection, likely due to the variability and small sample size 300 in each sex ( Fig. 2C and D) . Finally, transitions between dark and light zones were significantly 301 decreased by CGRP for both sexes (Fig. 2E and F) . 302 303

Since the cerebellum is well-known for motor control and the MN controls axial and trunk muscles 304

and maintains posture and balance (68), we tested the effect of CGRP delivery into the MN on gait. 305 We conducted the gait dynamic assay using DigiGait system. Injection of PBS or CGRP into the MN 306 did not change the stride length or frequency compared to their respective baselines across and within 307 sexes ( Supplementary Fig. 2 ). This indicates that CGRP administration into the MN decreases 308 motility without gait alterations. 309

the open field assay 311

To assess anxiety behavior independent of light, we used the open field assay. Inclusion of this assay 312 was necessary because spending less time in the light in the light/dark assay can be an indicator of an 313

increased anxiety state (76), and not necessarily a specific aversion to light. It is important to note 314 though that the two are not mutually exclusive since light aversion may include increased anxiety. 315

The mice injected with CGRP spent less time in the center than those injected with PBS during the 316 30-min testing time ( Fig. 3A and B, left) . However, when data were analyzed by sex, females 317 exhibited significantly less time in the center over the entire testing time ( Fig. 3A and B, middle), 318

while there was only a trend in males observed in the last 10 min ( Fig. 3A and B, right) . These data 319

suggest that CGRP delivery into the MN elicited general anxiety-like behavior primarily in female 320 mice, which may have contributed to their light-aversive behavior. 321

contralateral hind paw primarily in female mice 323

Cutaneous allodynia is present in approximately 60% of migraine patients with a higher prevalence 324 in women than men (82, 83). Thus, we investigated the effect of CGRP administration into the right 325 MN on tactile hypersensitivity as a generally accepted indicator of allodynia by measuring the tactile 326 sensitivity in the plantar area of the right and left hind paws. 327

In the contralateral left hind paw, there was a significant decrease in the withdrawal threshold 328 observed for all the CGRP-treated mice (Fig. 4A, left) . However, the difference is primarily driven 329 by effects in the female mice, who showed a significant decrease in the withdrawal threshold after 330 CGRP but not PBS injection compared to their respective baselines (Fig. 4A, middle) . The CGRP-331 induced decrease in the threshold was only a trend in male mice (Fig. 4A, right) . 332

In contrast, the ipsilateral right paw results were more complicated due to a significant decrease in 333

withdrawal threshold compared to baselines in response to not only CGRP, but also PBS vehicle 334 (Fig. 4B, left) . When separated by sex, there was a trend for female mice after PBS treatment and a 335 significant decrease after CGRP treatment compared to respective baselines (Fig. 4B, middle) . A 336 significant decrease was observed for male mice after either PBS or CGRP treatment (Fig. 4B , right) 337 compared to baselines. The decrease in males after CGRP treatment is similar to the vehicle effect 338 observed with PBS injection, suggesting that disturbance to the right MN is enough to increase 339 ipsilateral hind paw sensitivity. For the von Frey test, 7 of the 43 mice had injection sites not in or 340 near the MN. When comparing data between on-target mice and off-target mice, no difference was 341 observed between these two groups, but it should be noted that the off-target mice were 342 underpowered. Altogether, these data suggest that CGRP increases the contralateral left hind paw 343 touch sensitivity predominantly in female mice, while injection of either PBS vehicle or CGRP 344 increases sensitivity in the ipsilateral right hind paw. 345

The grimace scale was developed to evaluate spontaneous pain expression in mice (84). Our 347 laboratory found that orbital tightening, or squint, is the principal component of mouse grimace score 348

(85) and has developed an automated video-based squint assay to measure spontaneous pain (81). 349

Taking advantage of this sensitive automated squint platform, we asked whether mice squint after 350 CGRP injection in the MN. 351

For all mice, CGRP-treated mice showed a decrease in the mean pixel area over the 300-second 352 testing period, while no change was observed in the PBS-treated mice compared to their respective 353 baselines (Fig. 5A) . When data were separated by sex, CGRP-treated females showed a significant 354 decrease in the mean pixel area (Fig. 5B) , while CGRP-treated males only showed a trend (Fig. 5C ). 355

No difference was observed in female or male PBS-treated groups ( Fig. 5B and C, left and right). 356

These data suggest that CGRP injection into the MN induces squint behavior predominantly in 357 female mice. 358

To obtain an estimate of the likely diffusion of CGRP after injection into the MN, we used a 360 fluorescent CGRP analog. Fluorescein-15-CGRP is a full CGRP receptor agonist but has less potency 361 than CGRP as measured by cAMP production in HEK293T cells ( supports the hypothesis that the cerebellum contributes to migraine pathogenesis. 388

Photophobia is a subjective experience in which normal light causes discomfort (100-102). In this 390 study, we found that administration of CGRP into the MN induced light aversion in male and female 391

mice. In addition, CGRP evoked anxiety-like behavior in females, but only a trend in males. Thus, 392

we conclude that the light aversion induced in males is not solely driven by anxiety, while in females 393 the light aversion may be influenced by an overall increased anxiety level. Anxiety symptoms have 394 been reported to be positively correlated to light aversion in migraine patients with the possibility 395 that anxiety contributes to light aversion (103). In male mice, there appears to be a biphasic response 396

where an anxiety-like response may have occurred during the final 10 min of the assay. While not 397 significant, it suggests that the light aversion detected in males may be partially driven by increased 398 anxiety at later time points. 399

An unexpected finding was that both male and female mice were aversive to even dim light after 400 CGRP injection, analogous to migraine patients who report light hypersensitivity in dim light that 401

does not bother control subjects. We had previously reported that transgenic mice overexpressing the 402 CGRP receptor in the nervous system were sensitive to dim light (~55 lux) after i. (105, 106) . These data place the MN in a prime position 422

to assist in sensory integration and play a modulatory role in the nociceptive-and light-integrating 423 function of the thalamus. 424

It is striking to observe the apparent sexually dimorphic anxiety-like behaviors predominantly in 426 female mice after CGRP injection into the MN. These data are consistent with the higher prevalence 427 of anxiety disorders in women than men (107). The MN sends direct projections to the limbic system 428 including the amygdala (68), which is key to the anxiety circuitry (108), and projects to the 429 periaqueductal gray (PAG) (69, 109), which is critical for aversive and anxiety-like responses (110). 430

The observations of light-aversive behavior accompanied by increased anxiety levels in females are 431 reminiscent of the behavior induced by optical stimulation of the dorsal PAG (18). This evidence 432 might explain the anxiogenic effect of the MN. The possible mechanism for the sex difference in 433 anxiety (or the other behaviors, including plantar tactile hypersensitivity and squinting discussed in 434 Section 4.3) is not known. It is interesting to point out that sex differences appeared in human fMRI 435 studies when migraine patients were exposed to a noxious stimulus (111). In that study, female 436 migraine patients showed higher activation in the cerebellum and higher deactivation of cerebellar 437 functional connectivity with insula than males in response to noxious heat. Finally, it is possible that 438 there could be sexually dimorphic differences in the distribution pattern of CGRP receptor 439 components in the MN or in downstream brain regions. 440

Allodynia is the perception of pain induced by non-noxious stimuli. Nearly 60% of individuals with 442 migraine have cutaneous allodynia, specifically thermal and mechanical allodynia (82). Cutaneous 443 allodynia is associated with migraine frequency, severity, and disability, and is more common in 444 females (82, 83). Moreover, cutaneous allodynia is more frequent in chronic migraine than episodic 445 migraine (112) and is believed to be a predictor of migraine chronification (113). Allodynia in 446 migraine is found in cephalic and extracephalic regions, which could be explained by the 447 sensitization of the second-order trigeminal and third-order thalamic neurons (114). 448

In this study, we found that CGRP injection into the MN increases sensitivity in response to 449 mechanical stimuli in contralateral hind paws predominately in female mice, which is consistent with 450 the clinical finding that cutaneous allodynia is higher in women than in men (82, 83) and a preclinical 451 study where intraplantar CGRP at a low dose evoked hind paw allodynia only in female rats (115). 452

Given that we also observed anxiety behavior primarily in female mice, it is interesting that allodynia 453 is associated with a higher risk for anxiety and a correlation exists between their severity in migraine 454 patients (116). Anxiety was more prevalent in patients with migraine and probable migraine with 455 cutaneous allodynia than those without cutaneous allodynia (117). In animal models, stress elicited 456 higher pain sensitivity (118). These data suggest an association between anxiety and allodynia, so it 457 is possible that anxiety induced by CGRP injection in female mice is linked to the tactile 458 hypersensitivity indicative of allodynia. 459 

We observed increased resting time in the dark while no change in the light in the light/dark assay 480 across and within sex, corresponding to the preference of migraine patients to go to the dark and rest. 481

Vertical beam breaks and transitions were decreased, suggesting exploratory behavior was decreased. 482

The MN is responsible for controlling axial and trunk muscles, posture and balance (68). However, 483

we did not observe gait difference before or after PBS or CGRP treatment using the DigiGait system. 484

A recent study reported that an increase in light intensity could enhance postural sway in migraine 485 patients compared to controls (54), so perhaps additional triggers may be needed to detect such 486 effects in mouse models. Overall, these data suggest that CGRP injection into the MN does not 487 induce gait changes. 488

A caveat of this study is the broad diffusion area of CGRP. We used fluorescein-15-CGRP for 490 diffusion estimation. Extensive spread was observed from the MN with the injection of fluorescein-491 15-CGRP, which was not completely unexpected. The diffusion was similar (approximately 800-492 4000 μ m rostral to caudal) as when fluorescein-15-CGRP was injected into the posterior thalamic 493 region and was estimated to spread at least 1400 um in some cases (18). This is consistent with the 494 volume transmission reported for some peptides diffusing up to millimeters in the brain (120 A related caveat is that location of CGRP receptor subunits RAMP1 and CLR in the mouse 505 cerebellum has not been studied. Importantly, clusters of fluorescein-15-CGRP observed within the 506 MN are consistent with a prior report of MN CGRP receptors in the rat (65). Such clusters were also 507 found in the molecular, Purkinje cell and granular layers in the vermal lobules and simple lobule in 508 the hemisphere regions. Previous studies have reported RAMP1 and CLR co-expression in Purkinje 509 cells in the rat, human and rhesus cerebellum (61, 66). However, consistent data is lacking for 510 RAMP1 or/and CLR expression in the molecular layer or granular layer in the rat cerebellum (61, 65) 511 and no reports for mice, to our knowledge. In addition, the possible expression of the second CGRP 512 receptor (AMY1) (121) in the mouse cerebellum has not been explored. 513

We observed several responses to cerebellar CGRP that were only statistically significant in female 514

mice. However, we want to couch that observation with the prediction that if more mice were 515 analyzed, then the trends seen with male mice could also reach significance for the open field, von 516

Frey, and grimace assays. Because the study was designed to be sufficiently powered (see section 517 2.7), we did not try to further increase the number of male mice. However, to estimate how many 518 more mice might be required to reach significance, we did a post-hoc power analysis for each of the 519 assays. About twice the number of male mice is predicted to be needed to reach statistical 520 significance comparable to the females. Hence, as seen with human migraine populations, we are 521 seeing a quantitative bias for female responses and not an absolute female-only mechanism. 522

In conclusion, this study reveals that CGRP injection into the cerebellum is sufficient to induce 524 migraine-like behaviors primarily in female mice. This discovery provides a new perspective on the 525 increasingly complex neural circuitry of migraine pathophysiology and suggests a role for central 526 CGRP signaling in the sexual dimorphic nature of migraine. 527

Conflict of Interest 528 A.F.R. is a consultant for Lundbeck, Amgen, Novartis, Eli Lilly, AbbVie, and Schedule 1 529

Therapeutics. The authors declare no other competing financial interests. Numbers indicate the distance from bregma in the anteroposterior plane. Data are the mean ± SEM. 966

Statistics are described in Supplementary Table 1 . 967 

The Headache Pipeline: Excitement and Uncertainty

Peripheral and central nervous 584 system distribution of the CGRP neutralizing antibody

588 Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP 589 Mechanisms

Modulation of CGRP-induced light aversion in 592 wild-type mice by a 5-HT(1B/D) agonist

Role of calcitonin 600 gene-related peptide in light-aversive behavior: implications for migraine

How the cerebellum may 608 monitor sensory information for spatial representation

Integration of sensory and motor representations of 611 single fingers in the human cerebellum

Consensus Paper: Roles of the Cerebellum in Motor Control-The Diversity of Ideas on Cerebellar 615 Involvement in Movement

Consensus Paper: The 618 Role of the Cerebellum in Perceptual Processes

Consensus 624 Paper: Cerebellum and Social Cognition

Consensus 627 Paper: The Cerebellum's Role in Movement and Cognition

The therapeutic potential of the cerebellum in 630 schizophrenia

The cerebellum and pain: passive 633 integrator or active participator?

Interictal brain activity differs in 637 migraine with and without aura: resting state fMRI study

Amplitude of low-frequency 640 fluctuation (ALFF) and fractional ALFF in migraine patients: a resting-state functional MRI study

Brain 647 morphologic abnormalities in migraine patients: an observational study

Structural Changes in 650 the Cerebrum, Cerebellum and Corpus Callosum in Migraine Patients

Structural and functional 653 abnormalities in migraine patients without aura

Functional and structural alterations in the migraine cerebellum

Patterns of gray matter 659 alterations in migraine and restless legs syndrome

Volumetric 662 differences suggest involvement of cerebellum and brainstem in chronic migraine

Cerebral gray 665 matter volume in patients with chronic migraine: correlations with clinical features

Gray matter changes related to 669 medication overuse in patients with chronic migraine

Familial hemiplegic migraine, nystagmus, and 672 cerebellar atrophy

Familial hemiplegic 675 migraine in The Netherlands. Dutch Migraine Genetics Research Group

A gene for 679 familial hemiplegic migraine maps to chromosome 19

An altered GABA-A receptor function in 682 spinocerebellar ataxia type 6 and familial hemiplegic migraine type 1 associated with the CACNA1A 683 gene mutation

Magnetic resonance imaging in familial 686 paroxysmal ataxia

Altered functional 689 connectivity of the red nucleus and substantia nigra in migraine without aura

Functional Alterations in the 693 Posterior Insula and Cerebellum in Migraine Without Aura: A Resting-State MRI Study

Altered Hypothalamic 697 Functional Connectivity with Autonomic Circuits and the Locus Coeruleus in Migraine

Disrupted functional connectivity 701 between sub-regions in the sensorimotor areas and cortex in migraine without aura

Impaired functional connectivity 705 of limbic system in migraine without aura

Altered lateral geniculate 708 nucleus functional connectivity in migraine without aura: a resting-state functional MRI study

Central effects of erenumab in migraine 712 patients: An event-related functional imaging study

Postural instability during attacks of 717 migraine without aura

Static stabilometry in 720 patients with migraine and tension-type headache during a headache-free period

Functional organization of trigeminal subnucleus 727 interpolaris: nociceptive and innocuous afferent inputs, projections to thalamus, cerebellum, and 728 spinal cord, and descending modulation from periaqueductal gray

Differential expression of VGLUT1 or 734 VGLUT2 in the trigeminothalamic or trigeminocerebellar projection neurons in the rat

Cerebellum and psychiatric disorders

In vivo 741 quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey 742 and human brain using the positron emission tomography tracer [11C]MK-4232

746 Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide 747 receptor antagonist

Cerebellar distribution of calcitonin 750 gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) 751 and receptor activity modifying protein 1 (RAMP1) in rat

CGRP and 754 CGRP receptors in human and rhesus monkey cerebellum

Calcitonin gene-757 related peptide receptor expression in the neurons and glia of developing rat cerebellum: an 758 autoradiographic and immunohistochemical analysis

Monoclonal antibodies reveal expression of the CGRP 761 receptor in Purkinje cells, interneurons and astrocytes of rat cerebellar cortex

Distribution of CGRP and CGRP receptor components in the rat 765 brain

Localization of 768 CGRP Receptor Components, CGRP, and Receptor Binding Sites in Human and Rhesus Cerebellar 769 Cortex

Topographic 772 localization of calcitonin gene-related peptide in the rat brain: an immunohistochemical analysis

Cerebellar fastigial nucleus: from anatomic construction to 776 physiological functions

Protective effect and mechanism of 785 injection of glutamate into cerebellum fastigial nucleus on chronic visceral hypersensitivity in rats

PACAP Induces 800 Light Aversion in Mice by an Inheritable Mechanism Independent of CGRP

Investigating Migraine-804 Like Behavior using Light Aversion in Mice

Different 810 forms of traumatic brain injuries cause different tactile hypersensitivity profiles

Quantitative assessment of tactile 814 allodynia in the rat paw

The up-and-down Method for Small Samples

Automated 819 detection of squint as a sensitive assay of sex-dependent CGRP and amylin-induced pain in mice

Prevalence and 825 characteristics of allodynia in headache sufferers: a population study

Coding of 828 facial expressions of pain in the laboratory mouse

831 Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: 832 implications for migraine

Photoaffinity Cross-836 Linking and Unnatural Amino Acid Mutagenesis Reveal Insights into Calcitonin Gene

Peptide Binding to the Calcitonin Receptor-like Receptor/Receptor Activity-Modifying Protein 1 838 (CLR/RAMP1) Complex

Dynamic sodium imaging at 841 ultra-high field reveals progression in a preclinical migraine model

Altered functional connectivity of the insula in a rat model of 844 recurrent headache

Atypical functional connectivity between the 848 anterior cingulate cortex and other brain regions in a rat model of recurrent headache

Purkinje cells of vestibulocerebellum play an 852 important role in acute vestibular migraine

Function and dysfunction of synaptic calcium channels: insights from mouse 855 models

858 Contribution of calcium-dependent facilitation to synaptic plasticity revealed by migraine mutations 859 in the P/Q-type calcium channel

Anterior cerebellum as a site for morphine analgesia and post-stimulation 863 analgesia

Alteration of nociception by stimulation of cerebellar structures in the 866 monkey

The cerebellum: synaptic changes and fear conditioning

Epub 2005/05/25

Hypothalamic, dorsal raphe and external 872 electrical stimulation modulate noxious evoked responses of habenula neurons

Cerebellar stimulation modulates thalamic noxious-evoked 875 responses

Cerebellar cortical stimulation increases 878 spinal visceral nociceptive responses

Inhibition of spinal cord dorsal 881 horn neuronal activity by electrical stimulation of the cerebellar cortex

Shedding light on photophobia

Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine

Unanswered Questions in Headache: So What Is Photophobia, 890 Anyway?

Psychiatric comorbidities and 893 photophobia in patients with migraine

Current understanding of photophobia, visual 897 networks and headaches

Diverse Central 901 Projection Patterns of Retinal Ganglion Cells

Synapse formation and preferential distribution in the 905 granule cell layer by regenerating retinal ganglion cell axons guided to the cerebellum of adult 906 hamsters

Gender differences in anxiety disorders: 909 prevalence, course of illness, comorbidity and burden of illness

Topography of cerebellar 916 nuclear projections to the brain stem in the rat

Serotonin, the periaqueductal gray and panic

Her versus his migraine: 921 multiple sex differences in brain function and structure

Cutaneous 924 allodynia is more frequent in chronic migraine, and its presence and severity seems to be more 925 associated with the duration of the disease

Cutaneous allodynia as a predictor of migraine chronification

An association between 931 migraine and cutaneous allodynia

Dural Calcitonin 934

Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine Models

Psychiatric comorbidities in 938 allodynic migraineurs

Prevalence and characteristics 941 of cutaneous allodynia in probable migraine

CGRP Antibodies for Animal Models of Primary and 945 Secondary Headache Disorders

Altered 949 experimental pain perception after cerebellar infarction

and middle) and mean pixel area over 5-min testing period for individual male mice (right; PBS: 1008 n=13; CGRP: n=13). Data are the mean ± SEM. Statistics are described in Supplementary Table 1.  1009